Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Editorial

Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomization

Mohammad Saeid Rezaee-Zavareh, Naomy Kim, Ju Dong Yang

Clin Mol Hepatol. 2024;30(2):150-153. Published online February 22, 2024

DOI: https://doi.org/10.3350/cmh.2024.0116

View: 1478 Download: 43

Original Article

Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets

Yingzhou Shi, Hang Dong, Shiwei Sun, Xiaoqin Wu, Jiansong Fang, Jianbo Zhao, Junming Han, Zongyue Li, Huixiao Wu, Luna Liu, Wanhong Wu, Yang Tian, Guandou Yuan, Xiude Fan, Chao Xu

Clin Mol Hepatol. 2024;30(1):80-97. Published online December 7, 2023

DOI: https://doi.org/10.3350/cmh.2023.0343

View: 3096 Download: 159 Crossref: 1

Special topic: Alcoholic liver diseases The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)

Roles of the complement system in alcohol-induced liver disease

Yi Zhou, Guandou Yuan, Fudi Zhong, Songqing He

Clin Mol Hepatol. 2020;26(4):677-685. Published online October 1, 2020

DOI: https://doi.org/10.3350/cmh.2020.0094

View: 6594 Download: 141 Web of Science: 10 Crossref: 11

1 |

Viewed By 5561	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 4769	MAFLD: How is it different from NAFLD?
Viewed By 4501	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3680	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3660	Global incidence and prevalence of nonalcoholic fatty liver disease

Cited By 135	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 80	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 68	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 57	MAFLD: How is it different from NAFLD?

Search